Last Updated on February 13, 2022
The Food and Drug Administration (FDA) is postponing its advisory committee meeting on potential authorization for the Pfizer-BioNTech Coronavirus vaccine for babies as young as six months old. The FDA said that “new data” emerged in clinical trials, according to Pfizer, and so the FDA has postponed the meeting, which would have discussed emergency use authorization for the injection for children between the ages of six months and four years old. Obviously, this could be a massive setback for Pfizer-BioNTech’s efforts to inject children. As NATIONAL FILE reported days ago, the University of Pennsylvania — which hosts and directly funds Joe Biden’s think tank — profits off Pfizer-BioNTech vaccine sales and even profits off the Biden FDA’s approval of the vaccines, which represents a massive conflict of interest for Joe Biden. The FDA is still experiencing backlash after one of its advisory committee members, Eric Rubin, stated, “But we’re never going to learn about how safe the vaccine is unless we start giving it. That’s just the way it goes.” The FDA knew about numerous adverse events for children in past clinical trials but approved the injection anyway for ages 5 to 11. The FDA advisory committee that authorized the jab for 5-year olds was filled with Pfizer cronies. Not surprisingly, Pfizer’s fourth quarter earnings report discusses the possibility of unfavorable safety data for the vaccine and the risk of “serious” adverse reactions.
FDA Acting Director Janet Woodcock and an underling stated: “The U.S. Food and Drug Administration has been notified by Pfizer that new data have recently emerged regarding its emergency use authorization request for the use of the Pfizer-BioNTech COVID-19 Vaccine in children 6 months through 4 years of age. As part of its rolling submission, the company recently notified the agency of additional findings from its ongoing clinical trial. Based on the agency’s preliminary assessment, and to allow more time to evaluate additional data, we believe additional information regarding the ongoing evaluation of a third dose should be considered as part of our decision-making for potential authorization.Therefore, the FDA is postponing the Vaccines and Related Biological Products Advisory Committee meeting originally scheduled for Feb. 15.”
As NATIONAL FILE reported in November: The Food And Drug Administration (FDA) approved an emergency use authorization for the Pfizer-BioNTech vaccine for children as young as 5 years old despite the fact that its Pfizer-connected advisory committee knew about numerous adverse events that were reported in Pfizer’s clinical trials for children, including adverse events that were determined to be “related” to the clinical vaccine trial. The Briefing Packet for the FDA advisory committee meeting shows that the FDA advisers used clinical studies sponsored by BioNTech and conducted by or supported by Pfizer to approve the vaccine for young children. Talk about a conflict of interest! NATIONAL FILE reported on the FDA advisory committee’s massive Pfizer connections and how committee members have worked for Pfizer and are making money from the Pfizer vaccine. So what kind of adverse events were discovered in the clinical trials for children? The advisory committee meeting briefing packet, published by the FDA, shows that clinical trials found “related” illnesses including Lymphadenopathy, arthralgia, paresthesia, nervous tic, hematochezia (characterized by bloody stool, which sent the participant to the “emergency department”) pyrexia (fever), neutropenia (low white blood cell count), hypersensitivity reaction, angioedema, and rashes. Meanwhile, a case of the blood vessel disorder Henoch-Schoenlein purpura was reported but was conveniently classified as “non related” to the vaccine experiment.
